Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Erin F Barreto"'
Autor:
Heather P May, Joan M Griffin, Joseph R Herges, Kianoush B Kashani, Andrea G Kattah, Kristin C Mara, Rozalina G McCoy, Andrew D Rule, Angeliki G Tinaglia, Erin F Barreto
Publikováno v:
JMIR Research Protocols, Vol 12, p e48109 (2023)
BackgroundInnovative care models are needed to address gaps in kidney care follow-up among acute kidney injury (AKI) survivors. We developed the multidisciplinary AKI in Care Transitions (ACT) program, which embeds post-AKI care in patients’ primar
Externí odkaz:
https://doaj.org/article/3e06a3613bae4a88b53c7d281d97085a
Publikováno v:
PLoS ONE, Vol 18, Iss 1, p e0279928 (2023)
BackgroundDrug-induced nephrotoxicity is a relatively common preventable cause of acute kidney injury (AKI), providing early recognition and management. The pharmacokinetics or pharmacodynamics of drug-drug interactions may lead to additive or synerg
Externí odkaz:
https://doaj.org/article/e8d387db6cf8455697081e387d63d42e
Autor:
Rozalina Grubina McCoy, Kianoush B Kashani, Joan M Griffin, Heather Personett May, Abby K Krauter, Dawn M Finnie, Erin F Barreto
Publikováno v:
BMJ Open, Vol 12, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/454a769ec4db41a389f1078b60aed62e
Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic.
Autor:
James Roland Markos, Karen S Schaepe, Hilary R Teaford, Andrew D Rule, Kianoush B Kashani, John C Lieske, Erin F Barreto
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243618 (2020)
IntroductionSerum creatinine (SCr) testing has been the mainstay of kidney function assessment for decades despite known limitations. Cystatin C (CysC) is an alternative biomarker that is generally less affected than SCr by pertinent non-renal factor
Externí odkaz:
https://doaj.org/article/41358d8e2cdf44ffa45ba1a2858bab1f
Autor:
Lindsey M. Childs-Kean, Christina G. Rivera, Veena Venugopalan, Madelyn J. Johnson, Erin F. Barreto
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 4 (2024)
Beta-lactam therapeutic drug monitoring has been growing in prevalence in the acute care hospital setting. Expansion of its use to outpatient parenteral antimicrobial therapy requires careful consideration of potential logistical and therapeutic barr
Externí odkaz:
https://doaj.org/article/343bf3b0b8254084b863c657d9e6bb83
Autor:
Joseph R. Herges, Heather P. May, Laurie Meade, Brenda Anderson, Angeliki G. Tinaglia, Diana J. Schreier, Kianoush B. Kashani, Andrea Kattah, Rozalina G. McCoy, Andrew D. Rule, Kristin C. Mara, Erin F. Barreto
Publikováno v:
Journal of the American Pharmacists Association. 63:909-914
Development and performance of a novel vasopressor-driven mortality prediction model in septic shock
Autor:
Saraschandra Vallabhajosyula, Jacob C. Jentzer, Aditya A. Kotecha, Dennis H. Murphree, Erin F. Barreto, Ashish K. Khanna, Vivek N. Iyer
Publikováno v:
Annals of Intensive Care, Vol 8, Iss 1, Pp 1-9 (2018)
Abstract Background Vasoactive medications are essential in septic shock, but are not fully incorporated into current mortality prediction risk scores. We sought to develop a novel mortality prediction model for septic shock incorporating quantitativ
Externí odkaz:
https://doaj.org/article/ff1ec41b670a4ad79ff39c0c9815b0c5
Autor:
Jason N. Barreto, Erin F. Barreto, Kristin C. Mara, Andrew D. Rule, John C. Lieske, Callen D. Giesen, Carrie A. Thompson, Nelson Leung, Thomas E. Witzig, Kianoush B. Kashani
Publikováno v:
Kidney360. 4:673-679
Autor:
Caroline W. Grant, Erin F. Barreto, Rakesh Kumar, Rima Kaddurah-Daouk, Michelle Skime, Taryn Mayes, Thomas Carmody, Joanna Biernacka, Liewei Wang, Richard Weinshilboum, Madhukar H. Trivedi, William V. Bobo, Paul E. Croarkin, Arjun P. Athreya
Publikováno v:
Journal of Personalized Medicine, Vol 12, Iss 3, p 412 (2022)
Age at depressive onset (AAO) corresponds to unique symptomatology and clinical outcomes. Integration of genome-wide association study (GWAS) results with additional “omic” measures to evaluate AAO has not been reported and may reveal novel marke
Externí odkaz:
https://doaj.org/article/86a1394d6405461399e56ee3a03630b5
Autor:
Jade L. Kutzke, Julianna A. Merten, Amanda G. Pawlenty, Erin F. Barreto, Gabe T. Bartoo, Kristin C. Mara, Mark R. Litzow, William J. Hogan, Mithun V. Shah, Abhishek A. Mangaonkar, Nelson Leung, Hassan B. Alkhateeb
Publikováno v:
Blood Advances. 6:3844-3849
The reduced-intensity conditioning regimen, fludarabine and melphalan, is frequently used in allogeneic hematopoietic stem cell transplantation (HSCT). Melphalan and the active metabolite of fludarabine, F-ara-A, are excreted via the kidneys. Existin